Skip to main content

Advertisement

Table 1 Clinicopathological factors and expressions of FGFR1 to FGFR4 in DGC

From: Different clinical significance of FGFR1–4 expression between diffuse-type and intestinal-type gastric cancer

   FGFR1   FGFR2   FGFR3   FGFR4  
  Low High p Low High p Low High p Low High p
n 69 40   56 53   44 65   21 88  
Age (years)
  < 65 61 45 16 0.011 37 24 0.029 24 37 0.81 15 46 0.11
  ≥ 65 48 24 24 19 29 20 28 6 42
Gender
 Female 40 25 15 0.90 22 18 0.56 11 29 0.037 8 32 0.88
 Male 69 44 25 34 35 33 36 13 56
Main location
 Middle or lower 83 54 29 0.50 46 37 0.13 28 55 0.012 16 67 1.00
 Upper 26 15 11 10 16 16 10 5 21
Depth of invasion
 Early (T1) 35 29 6 0.004 26 9 0.001 18 17 0.11 12 23 0.006
 Advanced (T2/3/4) 74 40 34 30 44 26 48 9 65
LN metastasis
 Negative (N0) 45 35 10 0.009 30 15 0.007 19 26 0.74 16 29 <0.001
 Positive (N1/2/3) 64 34 30 26 38 25 39 5 59
Stage
 I 43 36 7 <0.001 30 13 0.002 21 22 0.15 16 27 <0.001
 II/III/IV 66 33 33 26 40 23 43 5 61
Distant metastasis or recurrence
 Negative 67 50 17 0.002 43 24 0.001 28 39 0.70 18 49 0.01
 Positive 42 19 23 13 29 16 26 3 39
Peritoneal dissemination
 Negative 82 58 24 0.005 46 36 0.086 35 47 0.39 18 64 0.22
 Positive 27 11 16 10 17 9 18 3 24
Hematogenous metastasis
 Negative 106 67 39 1.00 56 50 0.11 42 64 0.56 21 85 1.00
 Positive 3 2 1 0 3 2 1 0 3
HER2 score
 0–1 106 68 38 0.56 55 51 0.61 43 63 1.00 21 85 1.00
 2–3 3 1 2 1 2 1 2 0 3